Idiopathic pulmonary fibrosis: a decade of progress.
Although idiopathic pulmonary fibrosis remains a devastating diagnosis, recent advances have improved our understanding of many facets of this disease. These breakthroughs, combined with the increased general availability of therapeutic trials, hold the promise of a brighter future for idiopathic pulmonary fibrosis patients. For example, we now have a more comprehensive understanding of the diagnostic criteria and natural history of the disease. Several studies have shown that simple measurement of pulmonary physiology or gas exchange can be used to predict patient survival. By identifying several molecular pathways that play significant roles in the pathogenesis of idiopathic pulmonary fibrosis, investigators have produced a growing list of novel potential therapeutic targets for the disease. Several prospective, controlled therapeutic trials have been conducted. Others are ongoing or are still in the planning stages. These efforts have advanced our current knowledge of idiopathic pulmonary fibrosis and have raised new important questions, as well as having generated the interest and momentum needed to gain additional ground in the fight against this challenging disease. This article offers the reader a view of the recent advances in idiopathic pulmonary fibrosis research, with a focus on natural history, pathogenesis and treatment.
Swigris
Jeffrey J
JJ
Interstitial Lung Disease Program, National Jewish Medical and Research Center, Denver, Colorado 80206, USA.
Brown
Kevin K
KK
D002986:Clinical Trials as Topic; D006801:Humans; D011379:Prognosis; D011658:Pulmonary Fibrosis / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology